Table 1 Comparison of baseline information of patients in the training set and validation set.

From: DGPRI, a new liver fibrosis assessment index, predicts recurrence of AFP-negative hepatocellular carcinoma after hepatic resection: a single-center retrospective study

Characteristics

All patients N = 378

Training set N = 264

Validation set N = 114

p

Sex, n (%)

0.368

 Male

332 (87.8%)

235 (89.0%)

97 (85.1%)

 

 Female

46 (12.2%)

29 (11.0%)

17 (14.9%)

 

Age, n (%)

0.720

  < 60

229 (60.6%)

162 (61.4%)

67 (58.8%)

 

  ≥ 60

149 (39.4%)

102 (38.6%)

47 (41.2%)

 

Family history of malignant tumors, n (%)

0.535

 No

288 (76.2%)

204 (77.3%)

84 (73.7%)

 

 Yes

90 (23.8%)

60 (22.7%)

30 (26.3%)

 

Hypertension, n (%)

0.683

 No

256 (67.7%)

181 (68.6%)

75 (65.8%)

 

 Yes

122 (32.3%)

83 (31.4%)

39 (34.2%)

 

Diabetes, n (%)

0.383

 No

310 (82.0%)

220 (83.3%)

90 (78.9%)

 

 Yes

68 (18.0%)

44 (16.7%)

24 (21.1%)

 

Smoking, n (%)

0.473

 No

190 (50.3%)

129 (48.9%)

61 (53.5%)

 

 Yes

188 (49.7%)

135 (51.1%)

53 (46.5%)

 

HBV infection, n (%)

0.618

 No

111 (29.4%)

75 (28.4%)

36 (31.6%)

 

 Yes

267 (70.6%)

189 (71.6%)

78 (68.4%)

 

HCV infection, n (%)

0.951

 No

347 (91.8%)

243 (92.0%)

104 (91.2%)

 

 Yes

31 (8.20%)

21 (7.95%)

10 (8.77%)

 

BMI, n (%)

0.611

  < 28

322 (85.2%)

227 (86.0%)

95 (83.3%)

 

  ≥ 28

56 (14.8%)

37 (14.0%)

19 (16.7%)

 

Operation duration, n (%)

0.261

  ≤ 180

184 (48.7%)

123 (46.6%)

61 (53.5%)

 

  > 180

194 (51.3%)

141 (53.4%)

53 (46.5%)

 

Intraoperative blood loss, n (%)

0.506

  ≤ 200

251 (66.4%)

172 (65.2%)

79 (69.3%)

 

  > 200

127 (33.6%)

92 (34.8%)

35 (30.7%)

 

Intraoperative blood transfusion, n (%)

0.532

 No

341 (90.2%)

236 (89.4%)

105 (92.1%)

 

 Yes

37 (9.79%)

28 (10.6%)

9 (7.89%)

 

Number of tumors, n (%)

0.981

 Single

350 (92.6%)

245 (92.8%)

105 (92.1%)

 

 Multiple

28 (7.41%)

19 (7.20%)

9 (7.89%)

 

Edmondson Steiner grade, n (%)

0.242

 I-II

310 (82.0%)

212 (80.3%)

98 (86.0%)

 

 III-IV

68 (18.0%)

52 (19.7%)

16 (14.0%)

 

Maximum diameter of the largest tumor, n (%)

0.723

  < 5

289 (76.5%)

200 (75.8%)

89 (78.1%)

 

  ≥ 5

89 (23.5%)

64 (24.2%)

25 (21.9%)

 

Liver capsule invasion, n (%)

0.324

 No

216 (57.1%)

146 (55.3%)

70 (61.4%)

 

 Yes

162 (42.9%)

118 (44.7%)

44 (38.6%)

 

MVI, n (%)

0.822

 No

294 (77.8%)

204 (77.3%)

90 (78.9%)

 

 Yes

84 (22.2%)

60 (22.7%)

24 (21.1%)

 

Satellite nodule, n (%)

0.370

 No

357 (94.4%)

247 (93.6%)

110 (96.5%)

 

 Yes

21 (5.56%)

17 (6.44%)

4 (3.51%)

 

Scheuer scoring system, n (%)

0.905

 S0-S1

126 (33.3%)

89 (33.7%)

37 (32.5%)

 

 S2-S4

252 (66.7%)

175 (66.3%)

77 (67.5%)

 

AJCC-TNM staging, n (%)

0.561

 I

266 (70.4%)

186 (70.5%)

80 (70.2%)

 

 II

91 (24.1%)

63 (23.9%)

28 (24.6%)

 

 III

20 (5.29%)

15 (5.68%)

5 (4.39%)

 

 IV

1 (0.26%)

0 (0.00%)

1 (0.88%)

 

BCLC staging, n (%)

0.244

 0

69 (18.3%)

42 (15.9%)

27 (23.7%)

 

 A

288 (76.2%)

208 (78.8%)

80 (70.2%)

 

 B

16 (4.23%)

11 (4.17%)

5 (4.39%)

 

 C

5 (1.32%)

3 (1.14%)

2 (1.75%)

 

AFP, median [IQR]

4.22 [2.55;7.08]

4.08 [2.44;7.15]

4.73 [2.73;7.03]

0.454

HGB, median [IQR]

151 [142;160]

151 [143;160]

151 [138;160]

0.440

PLT, median [IQR]

164 [129;202]

167 [133;205]

158 [118;198]

0.144

ALT, median [IQR]

26.0 [20.0;40.0]

26.0 [20.0;39.2]

28.0 [20.2;40.4]

0.588

AST, median [IQR]

25.0 [20.0;33.0]

24.4 [20.0;32.0]

26.0 [21.0;34.0]

0.575

TBIL, median [IQR]

13.6 [9.90;17.2]

13.7 [9.97;17.1]

13.4 [9.90;17.6]

0.951

DBIL, median [IQR]

4.50 [3.40;5.80]

4.50 [3.50;5.80]

4.40 [3.30;5.90]

0.656

ALB, median [IQR]

44.5 [41.6;46.8]

44.2 [41.5;46.8]

44.9 [42.2;46.9]

0.159

LDH, median [IQR]

169 [147;191]

170 [146;191]

166 [149;189]

0.874

GGT, median [IQR]

40.0 [26.0;63.9]

39.4 [26.0;62.4]

41.0 [25.2;68.8]

0.529

DGPRI, n (%)

0.673

  < 1.85

177 (46.8%)

126 (47.7%)

51 (44.7%)

 

  ≥ 1.85

201 (53.2%)

138 (52.3%)

63 (55.3%)

 

Adjuvant therapy, n (%)

0.549

 No

299 (79.1%)

211 (79.9%)

88 (77.2%)

 

 Yes

79 (20.9%)

53 (20.1%)

26 (22.8%)

 
  1. HBV hepatitis B virus, HCV hepatitis C virus, BMI body mass index, MVI microvascular invasion, AJCC-TNM American Joint Committee on Cancer tumor–node–metastasis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, HGB hemoglobin, PLT platelet, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, ALB albumin, LDH lactate dehydrogenase, DBIL Direct bilirubin, GGT gamma-glutamyl transpeptidase, DGPRI DBIL-GPR index.
Back to article page